Peginterferon alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy

International Journal of Medical Sciences

Volumn 10, Issue 1, 2012, Pages 43-49

  Kanda, Tatsuo ^a   Nakamoto, Shingo ^a   Nishino, Takayoshi ^b   Takada, Nobuo ^c   Tsubota, Akihito ^d   Kato, Keizo ^e   Miyamura, Tatsuo ^a   Maruoka, Daisuke ^a   Wu, Shuang ^a   Tanaka, Takeshi ^a   Arai, Makoto ^a   Mikami, Shigeru ^f   Fujiwara, Keiichi ^a   Imazeki, Fumio ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NARITA RED CROSS HOSPITAL   (Japan)

^f Department of Medicine   (Japan)

Author keywords

HCV G2; Japanese; Retreatment

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JAPANESE; MALE; MONOTHERAPY; PATIENT SELECTION; RELAPSE; RETREATMENT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

HCV G2; JAPANESE; RETREATMENT;

AGED; ANTIVIRAL AGENTS; DRUG SYNERGISM; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERFERONS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA; TREATMENT OUTCOME;

EID: 84871356915     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.5358     Document Type: Article

References (30)

1. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997; 26 (3 Suppl 1): 34S-38S.
2. Kanda T, Imazeki F, Mikami S, et al. Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients. Oncology. 2011; 80: 366-372.
3. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005; 42: 962-973.
4. Takano S, Yokosuka O, Imazeki F, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995; 21: 650-655.
5. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005; 352: 2609-2617.
6. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005; 357: 124-134.
7. Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int. 2010; 4: 548-561.
8. Yu ML, Dai CY, Huang JF, et al. A randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007; 56: 553-559.
9. Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 2008; 47: 1837-1845.
10. Yokosuka O, Iwama S, Suzuki N, et al. High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and/or HCV genotype 2. A prospective study. Intervirology. 2004; 47: 328-334.
11. Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012; 6: 409-435.
12. Sherman M, Yoshida EM, Deschenes M, et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut. 2006; 55: 1631-1638.
13. Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2a and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology. 2009; 136: 1618-1628.
14. Kanda T, Imazeki F, Azemoto R, et al. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig Dis Sci. 2011; 56: 3335-3342.
15. Etoh R, Imazeki F, Kurihara T, et al. Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response. BMC Res Notes. 2011; 4: 316.
16. Kanda T, Imazeki F, Yonemitsu Y, et al. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test. J Viral Hepat. 2011; 18:e292-297.
17. Tsukiyama-Kohara K, Yamaguchi K, Maki N, et al. Antigenicities of Group I and II hepatitis C virus polypeptides-molcular basis of diagnosis. Virology. 1993; 192:430-437.
18. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology. 1994; 19: 1347-1353.
19. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002; 123: 1061-1069.
20. Matsuda F, Torii Y, Enomoto H, et al. Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C. J Viral Hepat. 2012; 19: 694-703.
21. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362: 1292-1303.
22. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364: 2417-2428.
23. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 1207-1217.
24. Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology. 2011; 141:881-889.
25. Mangia A, Mottola L. What's new in HCV genotype 2 treatment. Liver Int. 2012; 32 Suppl 1: 135-140.
26. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461: 399-401.
27. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41: 1105-1109.
28. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41: 1100-1104.
29. Miyamura T, Kanda T, Nakamoto S, et al. Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS One. 2011; 6: e28617.
30. Yu ML, Huang CF, Huang JF, et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology. 2011; 53: 7-13.